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Background: Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy
efficacy against HCC is still unsatisfactory. The mammalian target of rapamycin (mTOR) has been emerged as an
important cancer therapeutic target. However, HCC cells often resistant to rapamycin because of the paradoxical
activation of Akt by rapamycin. In this study, we investigated whether bortezomib could enhance the antitumor
effects of rapamycin.
Methods: The effects of rapamycin and bortezomib on HCC proliferation, apoptosis, migration, and invasiveness
in vitro were assessed by CCK-8 analysis, flow cytometry, Hoechst 33342 staining and transwell assays, respectively.
Total and phosphorylated protein levels of Akt were detected by Western blotting. The effects of rapamycin and/or
bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by
RT-PCR. The roles of rapamycin and bortezomib on HCC growth and metastasis in xenograft models were evaluated
by tumor volumes and fluorescent signals. The effects of rapamycin and bortezomib on cell proliferation and
apoptosis in vivo were test by PCNA and TUNEL staining.
Results: Bortezomib synergized with rapamycin to reduce cell growth, induce apoptosis, and inhibit cell mobility
in vitro. Further mechanistic studies showed that bortezomib inhibited rapamycin-induced phosphorylated Akt,
which in turn enhanced apoptosis of HCC cell lines. The alteration of the mRNA expression of cell cycle inhibitors
p53, p27, p21 and apoptosis associated genes Bcl-2, Bax were also involved in the synergistic antitumor effects
of rapamycin and bortezomib. P53 inhibitor PFT-α significantly attenuate the effect of rapamycin and bortezomib
on cell apoptosis, which indicated that the pro-apoptotic effect of rapamycin and bortezomib may be
p53-dependent. Treatment of HCCLM3-R bearing nude mice with rapamycin and bortezomib significantly
enhanced tumor growth inhibition (72.4%), comparing with either rapamycin- (54.7%) or bortezomib-treated mice
(22.4%). In addition, the lung metastasis was significantly suppressed in mice received the combination treatment
(16.6%). The combination treatment of rapamycin and bortezomib significantly inhibited tumor cell proliferation
and tumor angiogenesis in vivo.
Conclusion: The combination of rapamycin with bortezomib could be a novel and promising therapeutic
approach to the treatment of HCC.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon solid tumor in the world and the third most com-
mon cause of cancer mortality [1]. To date, surgical
resection and liver transplantation surgery is still the
only potential curative treatment for patients with early-
stage tumors (Barcelona Clinic Liver Cancer classifica-
tion, BCLC 0 and A). However a considerable number of
patients with advanced HCC are not suitable for surgery
because of metastases [2]. Systemic pharmacotherapy
is the main treatment for those patients (BCLC stage
C and D). Unfortunately, traditional chemotherapy treat-
ments show little efficacy in patients with advanced
HCC and often have no survival benefit [3,4].
Recently, drugs that targeting key pathways have gen-
erated new perspectives in the field of the treatment of
HCC. Sorafenib is the first and only systemic therapy
to significantly prolong the survival of HCC patients
with advanced-stage disease [5]. However, the tumor
response rates to the treatment of are usually low [6].
And emerging preclinical findings from our institute
revealed that invasiveness and metastatic behavior of
tumor cells are increased after a long period treatment
of sorafenib. Therefore, novel and effective pharma-
cological strategies for the treatment of advanced HCC
are critically needed.
The mTOR pathway is aberrant activated in a propor-
tion of HCC [7]. Inhibition of mTOR had been shown to
suppress the liver tumor growth and metastasis [8,9].
Emerging clinical evidence as well as preclinical findings
revealed that the mTOR inhibitor rapamycin and its
analogues can be used in treating solid tumors, such as
esophageal squamous cell carcinoma [10], lung cancer
[11], renal cell carcinoma [12] and prostate cancer [13].
These reports imply that mTOR pathway could be a
promising target for the treatment of HCC. Although
rapamycin has shown preclinical promise, it exhibited
little activity in HCC patients and the clinical outcomes
are mostly unpredictable when rapamycin used as single
agent. Recently, more studies have found that rapamycin
could paradoxically activate Akt while blocking mTOR,
which is a crucial mechanism accounting for rapamycin
resistance. Sun et al. demonstrated that treatment of
human lung cancer cells with rapamycin concurrently
increased the phosphorylation of both Akt and eIF4E
[14]. It also has been reported that mTOR inhibition will
enhance insulin receptor substrate-1 expression and
abrogate feedback inhibition of the pathway, resulting in
Akt activation both in cancer cell lines and in patient
tumors [15]. Moreover, disrupting mTORC1 by rapamy-
cin may induce mTORC2 activation which is important
for Akt phosphorylation [16]. The activation of Akt
survival pathway can promote cell survival and inhibit
apoptosis by a variety of routes [17]. Therefore wehypothesized that the combined use of an agent which can
prevent Akt activation may potentialize the antitumor
activity of rapamycin.
Bortezomib is the first clinically available proteasome
inhibitor, which is often used in the treatment of
hematological malignancies [18]. Multiple clinical trials
have demonstrated that this small molecule possesses
antitumor activity in a variety of human cancers, including
HCC [19,20]. A multicenter, single-arm, phase II trial that
evaluates the activity of bortezomib in HCC has been
already conducted [21]. It is well known that bortezomib
can exert its antitumor activity against cancer cells
through inhibition of NF-КB activation by preventing IКB
degradation [22]. Accumulating studies indicate that
down-regulation of p-Akt is another potential mechanism
of bortezomib-induced apoptosis in HCC cells [19]. Borte-
zomib down-regulates p-Akt in a dose- and time-
dependent manner, which may be mediated by protein
phosphatase 2A (PP2A) and cancerous inhibitor of protein
phosphatase 2A (CIP2A) [23,24]. A combination therapy
of bortezomib with sorafinib or tumor necrosis factor sig-
nificantly down-regulates the expression of p-Akt and
induces apoptosis of HCC cell lines [24,25]. Previous study
has shown that mTOR inhibitors could have a role in
combination with weekly bortezomib for the treatment of
patients with relapsed and refractory multiple myeloma
[26]. However there are no available clinical data on the
combination of bortezomib and mTOR inhibitors on solid
tumors.
In this study, we investigated the efficacy of the com-
bination of rapamycin and bortezomib in HCC cells and
orthotopic tumor model with the aim of developing
novel HCC treatment approach.
Methods
Cell lines and materials
HCCLM3, a human HCC cell line with high metastatic
potential that originated from MHCC97, was established
by the Liver Cancer Institute of Fudan University
(Shanghai, China) [27]. Stable red fluorescent protein-
expressing HCCLM3 (HCCLM3-R) cells by infection
with lentivirus containing full-length cDNA of red fluor-
escent protein were also established by our institute [28].
SMMC7721 was established by the Shanghai Institute of
Cell Biology, Chinese Academy of Sciences. The cells
were maintained at 37°C with a 5% CO2 in DMEM sup-
plemented with 10% fetal bovine serum and antibiotics
(100 U/ml penicillin, 100 mg/ml streptomycin). Rapamy-
cin and bortezomib were purchased from LC Lab
(Woburn, MA). Both drugs were dissolved in DMSO,
and the final concentration of DMSO in the cell culture
studies was 0.1% or less. Most of the in vitro assays were
performed use the following concentration: rapamycin
(10 ng/ml) and Bortezomib (100 nM) or indicated
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zomib were based on previous study [8,24]. Chemical
inhibitor of p53, pifithrin-α (PFT-α) was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies
for western blot such as anti-Akt, anti-p-Akt Ser473
and anti-GAPDH were purchased from Cell Signaling
Technology (Danvers, MA). Other antibodies such as
anti-PCNA, anti-CD31 were obtained from Abcam
(Hong Kong, China). Cell Counting kit and colorimetric
TUNEL system were purchased from Dojindo (Kumamoto,
Japan) and Promega (Madison, WI), respectively.Cell proliferation assay
To determine the effect of rapamycin and bortezomib
on cell proliferation, we used a tetrazolium reagent,
2-(4-indophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2
H-tetrazolium monosodium salt (CCK8, Cell Counting
kit). In brief, 1× 103 cells were seeded in 96-well culture
plates. After an attachment period of 24 h, the cells were
cultured in the presence of vehicle, rapamycin (10 ng/ml),
bortezomib (100 nM), or a combination of both for 72 h.
At the time of 24 h, 48 h and 72 h, the cells were incubated
with CCK8 reagent for 1 h at 37°C. The staining intensity
in the medium was measured by determining the absorb-
ance at 450 nm.Cell cycle analysis
HCCLM3 and SMMC7721 cells plated on 20-cm2 tissue
culture flasks were collected at 24 h after the incubation
with vehicle, rapamycin (10 ng/ml), bortezomib (100 nM),
or the combination of rapamycin and bortezomib. Then,
the cells were fixed in 70% cold ethanol for 1 h and
resuspended in a hypotonic propidium iodide (PI) solution
(Sigma, St Louis, MO) containing RNase. Flow cytometry
was performed with the use of Coulter epic flow cyt-
ometer. DNA histograms were analyzed using Modfit
computer program (Verity Software House, Topsham,
ME, USA). In addition, the percentage of apoptotic cells in
the sub-G1 fraction was also calculated.Analysis of apoptotic cells by Hoechst 33342 staining
The chromatin dye Hoechst 33342 was used to assess
apoptotic cells. The cells were incubated with vehicle,
rapamycin (10 ng/ml), bortezomib (100 nM), or the com-
bination of rapamycin and bortezomib for 24 or 48 h.
After washing three times with PBS, the cells were fixed in
4% formaldehyde at room temperature for 30 min, then
washed twice with PBS and exposed to 5 μg/ml Hoechst
33342 for 30 min at room temperature. Afterwards, the
cells were observed with a fluorescence microscope. Apop-
totic cells were characterized by morphological alterations
such as condensed nuclei and cell shrinkage.Cell migration assay and cell invasion assay
Cell migration was performed by transwell assay
(Corning Costar, Cambridge, MA). The cells were incu-
bated with vehicle, rapamycin (10 ng/ml), bortezomib
(100 nM), or the combination of rapamycin and bortezo-
mib for 24 h. Then 5 × 104 pretreated cells in serum-free
DMEM were seeded on a membrane (8.0-μm pore size)
inserted in a well of a 24-well plate. DMEM containing
10% FBS was added to the lower chamber of each well.
After 48 h, cells in the upper chamber were removed by
cotton swab and the cells that had reached the underside
of the membrane were fixed with 4% paraformaldehyde
and stained with 10% Giemas for 10 min. The cells
that located on the underside of the filter (5 fields/filter)
were counted. The cell invasion assay was carried out simi-
larly, except that the matrigel (BD Biosciences) was added
to each well 6 h before cells were seeded on the membrane.
Western blot analysis
Equal amounts of total proteins (20 μg) were separated
by 10% SDS-PAGE and transferred to a 0.45-mm PVDF
membrane using a Bio-Rad SemiDry apparatus. The
membranes were blocked at room temperature for 1 h
with 5% nonfat milk in TBS containing Tween 20
(TBST). Then membranes were incubated with rabbit
anti-Akt, rabbit anti-p-Akt Ser473, or mouse anti-
GAPDH overnight at 4°C, followed by HRP-conjugated
secondary antibodies for 1 h at room temperature. After
washing three times in TBST, the membrane was incu-
bated with Chemiluminescent Detection Reagent for
5 min and exposed to X-ray film.
RT-PCR
Total RNA was extracted using Trizol Reagent (Invitrogen,
Carlsbad, CA) and was reverse-transcribed into comple-
mentary DNA with oligo (dT)18 primer using TransScript
first-strand cDNA synthesis kit (Transgene Biotech, China)
according to the manufacturer’s instructions. PCR was
performed with PCR kit (Lifefeng, China) according to the
manufacturer’s instructions. The primer sequences,
annealing temperature, number of cycles used for PCR,
and length of the amplified products can be seen in
Additional file 1: Table S1. The PCR products were
analyzed on 1.5% agarose gel and visualized under UV
light following ethidium bromide staining. Quantitative
data were expressed by normalizing the densitometric
units to GAPDH (internal control).
Orthotopic tumor model
Male BALB/C nude mice (5- to 6-week-old) were
obtained from Shanghai Institute of Materia Medica
(Chinese Academy of Sciences, Shanghai, China). The
in vivo experiments were carried out strictly in accord-
ance with a protocol approved by the Shanghai Medical
Wang et al. BMC Cancer 2012, 12:166 Page 4 of 14
http://www.biomedcentral.com/1471-2407/12/166Experimental Animal Care Committee (Permit Number:
2009–0082). HCCLM3-R hepatocellular cancer orthoto-
pic xenograft model was established as described previ-
ously [29,30]. Briefly, HCCLM3-R cells (5 × 106) were
injected subcutaneously into the upper left flank region
of nude mice. When the tumor reached 1 cm in diam-
eter, they were cut into 2 × 2 × 2 mm3 sized pieces, and
implanted into livers of 24 nude mice. The 24 mice
were randomly assigned to four experimental groups
(6 mice/group): control, rapamycin, bortezomib, and the
combination of rapamycin with bortezomib. Both drugs
were dissolved in DMSO and then diluted in saline, and
the final concentration of DMSO in the in vivo studies
was less than 0.1%. On day 4 after the tumor implant-
ation, rapamycin was delivered orally at a dose of
2 mg/kg every day. Bortezomib was administered as i.p.
injections at a dose of 0.5 mg/kg in 100 μL of 0.9% saline
solution twice a week. The dosage of rapamycin and
bortezomib is based on previous studies [9,25]. The mice
treated with both rapamycin and bortezomib was admi-
nistered by using the same schedule as described for
the single drug treatment. Control mice were received
100 μL of saline orally (every day) and 100 μL of saline
by i.p. injections (twice a week) including the same
concentration of DMSO with the treatment groups.
The treatment was stopped on day 33. Then the mice
were sacrificed on day 35 after tumor implantation. At
necropsy, tumor was measured for largest (a) and smal-
lest (b) diameters, and the tumor volume was calculated
as V= a × b2/2. The lungs were excised, and red fluores-
cent protein-positive metastatic foci were imaged by
fluorescent imaging (Leica MZ6). Then, orthotopic
tumors and lungs were fixed with 10% buffered formalin
and embedded with paraffin. Lung metastasis was also
determined by examining serial sections of every lung
tissue block by microscopy.
Immunohistochemistrical staining for Akt, p-Akt, PCNA
and CD31
Tumor tissue was fixed, embedded, and sliced into 5 μm
thick sections. Immunostaining of Akt, p-Akt Ser473,
PCNA and CD31 was carried out as described previously
[31]. Briefly, paraffin sections were first deparaffinized
and then hydrated. After microwave antigen retrieval,
endogenous peroxidase activity was blocked with incuba-
tion of the slides in 0.3% H2O2, and non-specific binding
sites were blocked with 10% goat serum. Then the sec-
tions were incubated with primary antibodies (rabbit
anti-Akt, rabbit anti-p-Akt Ser473, rabbit anti-PCNA
and mouse anti-CD31) overnight at 4°C, followed by
HRP-conjugated secondary antibodies for 1 h at room
temperature. Finally, the sections were developed in
diaminobenzidine solution under a microscope and
counterstained with hematoxylin. The proliferation indexwas determined as number of PCNA-positive cells/total
number of cells in 5 randomly selected high-power fields
(magnification × 200).
In situ apoptosis detection by TUNEL staining
Paraffin-embedded, 5 μm thick sections were used to
identify apoptotic cells by staining using TUNEL assay
kit according to the manufacturer’s instructions. The
extent of apoptosis was evaluated by counting the
TUNEL-positive cells (brown-stained). The apoptotic
index was determined as number of TUNEL-positive
cells/total number of cells in 5 randomly selected high-
power fields (magnification × 200).
Statistics
Analysis was performed with SPSS 15.0 for Windows.
In vitro cell proliferation, apoptosis migration and
invasion assays were analyzed by Student's t-test. Tumor
volumes and histologic quantitations were also compared
by Student’s t test. Categorical variables were tested with
the use of Fisher’s exact test. P <0.05 were considered
statistically significant.
Results
Combined treatment with rapamycin and bortezomib
inhibits HCC cell proliferation
CCK8 analysis was performed to test the effect of
rapamycin and bortezomib on proliferation of HCCLM3
and SMMC7721 cells. The cells were cultured in the
presence of vehicle, rapamycin (10 ng/ml), bortezomib
(100 nM), or a combination of rapamycin and bortezo-
mib for 24, 48, and 72 h, respectively. Growth of
HCCLM3 and SMMC7721 was significantly inhibited by
each drug alone. The combination of both drugs further
decreased the proliferation rate of HCCLM3 and
SMMC7721, compared to single drug application. The
inhibition rates of HCCLM3 and SMMC7721 in the
combined treatment group at 72 h were 77.9% and
69.3%, respectively (Figure 1A and Additional file 2:
Figure 1A).
Then, we examined whether treatment of cells with
rapamycin and/or bortezomib would change cell cycle by
single-cell analysis using flow cytometry. Rapamycin
(10 ng/ml) did block G1 to S transition of HCCLM3 and
SMMC7721 cells. Bortezomib (100 nM) induced cell cycle
arrest at the G2-M phase. Similar results were observed
upon treatment of the cells with rapamycin plus bortezo-
mib (Figure 1B, Additional file 2: Figure S1B).
Combined treatment with rapamycin and bortezomib
induces cell apoptosis
HCCLM3 cells were cultured in the presence or absence
of rapamycin, bortezomib, or their combination for 24
and 48 h, respectively. Apoptosis of those cells was
Figure 1 Combined treatment with rapamycin and bortezomib inhibited cell proliferation and enhanced cell apoptosis. (A) Proliferation
of HCCLM3 cells was evaluated by using Cell Counting Kit-8 (CCK-8) at indicated time points. (B) HCCLM3 cells were treated with rapamycin
(10 ng/ml), bortezomib (100 nM) or both agents. ModFit software analysis of flow cytometry histograms revealed that rapamycin treatment
resulted in cell cycle arrest at G1-S phase. Bortezomib significantly increased in the percentage of cells in the G2/M phase. When the two agents
were combined, no significant difference in cell cycle distribution was observed compared with bortezomib alone. (C) HCCLM3 cells were treated
with rapamycin (10 ng/ml), bortezomib (100 nM) or the combination for 24 or 48 h and stained with Hoechst 33342, the apoptotic nuclear
changes (arrows) were examined by fluorescence microscopy (magnification, ×400). (D, E) The quantification of apoptotic cells induced by
rapamycin and bortezomib was further confirmed by flow cytometry analysis. The sub-G1 contents were designed as apoptotic cells. * P< 0.01,
versus control group; ** P< 0.001, versus control group; # P< 0.05, versus bortezomib treatment group at 24 h; † P< 0.01, versus bortezomib
treatment group at 48 h. (F) The cells were treated with various concentrations of the drugs for 24 h, and then evaluated by using Cell Counting
Kit-8. † P< 0.01, versus bortezomib treatment group.
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As shown in Figure 1C, most cells from the control had
big, regular nuclei, with only a few cells showing apop-
totic nuclei with condensed chromatin by Hoechst 33342
staining analysis. Rapamycin did not induce apoptosis of
HCCLM3 cells, but bortezomib did. When the cells were
cultured in the presence of both rapamycin and bortezo-
mib, rapamycin potentiated the apoptotic effect of borte-
zomib from 16.4 ± 5.8% to 27.4 ± 6.2% (P< 0.05) at 24 h
and 30.7 ± 7.4% to 53.6 ± 9.4% (P< 0.01) at 48 h.
To further confirm the effect of rapamycin and borte-
zomib on cell apoptosis, FACS analysis was used to
assess apoptosis by detection of sub-G1 phase through
PI staining. As shown in Figure 1D, rapamycin did not
significantly induce apoptosis of HCCLM3 cells at 24 or
48 h compared with the control (P> 0.05). However, bor-
tezomib significantly induced 15.2 ± 2.1% of HCCLM3
cells to apoptotic death at 24 h and 25.5 ± 2.3% at 48 h. In
comparison with bortezomib alone, the combination of
rapamycin and bortezomib significantly enhanced apop-
tosis of HCCLM3 cells to 20.7 ± 2.4% at 24 h and
44.8± 5.8% at 48 h (Figure 1D and E).
Then different concentrations of single agent or in paral-
lel were used to further confirm the synergistic activity of
the combined treatment through CCK8 assay. Rapamycin,
as single agent, did not induce apoptosis of HCCLM3
cells. Bortezomib induced cell apoptosis in dose dependent
fashion. Combination of rapamycin and bortezomib
caused synergistic effects on cell apoptosis (Figure 1F). In
comparison with bortezomib alone, the synergistic effects
of rapamycin and bortezomib was noted to be significantly
different from single agent treatment at bortezomib con-
centrations of 100 and 1000 nM (P< 0.01).
Then we used another HCC cell line SMMC 7721 to
further validate the synergistic effect of rapamycin and
bortezomib. As shown in Additional file 3: Figure S2, rapa-
mycin did not induce significant apoptosis of SMMC7721
cells at 24 or 48 h. Treatment of SMMC7721 cells with
rapamycin and bortezomib significantly increased bortezo-
mib induced cell apoptosis at 48 h, even though bortezo-
mib alone have significantly increased apoptotic cell death.
Effects of rapamycin and bortezomib on migration and
invasion of HCCLM3
Migration and invasion assay in vitro were carried out to
evaluate the effects of rapamycin and bortezomib on
HCCLM3 cell mobility. In the migration assay, 10 ng/ml
of rapamycin significantly inhibited migration of HCCLM3
cells compared with the control (P< 0.05, Figure 2A and
C). In contrast, bortezomib alone, at 100 nM, did not sig-
nificantly affect on HCCLM3 cell migration. The suppres-
sion of transwell migration was significantly greater in the
combination of rapamycin and bortezomib in comparison
with rapamycin alone (P< 0.01, Figure 2A and C). In theinvasion assay, rapamycin or bortezomib significantly
reduced the number of pretreated HCCLM3 cells invading
the matrigel coated membrane, with 2.29-fold and 1.58-
fold decrease, respectively, compared with the untreated
controls (P< 0.01, Figure 2B and D). The combination of
rapamycin and bortezomib didn’t affect cell invasion fur-
ther compared with either single agent (Figure 2B and D).
Rapamycin induces p-Akt in HCCLM3 cells, whereas
bortezomib suppresses p-Akt
To confirm the effects of rapamycin on the expression of p-
Akt in HCCLM3 cells, the cells were exposed to increasing
concentrations of rapamycin for 24 h. Rapamycin increased
phosphorylation of Akt at Ser473, starting at doses as low
as 1 ng/ml. Activation of p-Akt was observed as early as 3 h
after exposure of HCCLM3 cells to 10 ng/ml of rapamycin
and this effect can last at least for 24 h (Figure 3A). To
examine the effects of bortezomib on p-Akt in HCCLM3
cells, the cells were cultured in the presence of increasing
doses of bortezomib (10–1000 nM) for 24 h. As shown in
Figure 3B, bortezomib suppressed p-Akt in a dose-
dependent manner. Although a slight activation of p-Akt
was observed at 3 h exposure of HCCLM3 cells to 100 nM
of bortezomib, bortezomib suppressed p-Akt when the
exposed time prolonged.
The p-Akt level was tested when rapamycin was added to
HCC cells for 3–6 h prior to the addition of bortezomib.
We found that rapamycin-mediated Akt phosphorylation
could be significantly suppressed after the cells were cul-
tured for 24 h in the presence of bortezomib at the concen-
tration of 100 nM (Figure 3C). Next, we incubated the cells
with rapamycin (10 ng/ml), bortezomib (100 nM), or the
combination of both agents for 24 h to study their effects
on p-Akt. Rapamycin increased p-Akt, which was abrogated
by bortezomib in the combined treatment. There was no
significant change in total Akt expression under those treat-
ment conditions (Figure 3D and E). Similar results were also
observed in SMMC7721 cells (Additional file 4 Figure S3).
The pro-apoptotic effect of rapamycin plus bortezomib is
dependent on p53 activity
The effects of rapamycin and/or bortezomib on the
mRNA expression levels of p53, p27, p21 and Bcl-2 family
in HCCLM3 cells were evaluated by RT-PCR. As shown in
Figure 4, the level of p53, p27, p21 or Bax mRNA expres-
sion was significantly up-regulated after the treatment of
HCCLM3 cells with either single agent or the combination
of both agents as compared with the control. The mRNA
level of Bcl-2 was significantly suppressed by the combin-
ation treatment. Rapamycin and/or bortezomib did not
affect the expression levels of other Bcl-2 family members,
Bim, Bid, Bak, and Bcl-xl (Figure 4A and B).
Following the discovery that rapamycin plus bortezo-
mib increased p53 mRNA expression in HCCLM3
Figure 2 Effects of rapamycin and bortezomib on migration and invasion of HCCLM3. (A, C) The transwell assay demonstrated that
rapamycin and combined treated cells migrated through the membrane in less number compared with control group. The inhibitory effect of
migration was markedly enhanced by combined treatment. (B, D) Rapamycin or bortezomib significantly inhibited cell invasion, as compared with
control group. No significant difference was observed between rapamycin treatment alone and combined treatment (magnification, ×400). *
P< 0.05, versus control group; ** P< 0.01, versus control group; # P< 0.01, versus rapamycin treatment group.
Wang et al. BMC Cancer 2012, 12:166 Page 7 of 14
http://www.biomedcentral.com/1471-2407/12/166cells, we determined whether the pro-apoptotic effect
was dependent on p53 activity. HCCLM3 cells treated
with the p53 inhibitor PFT-α abrogated p53 expression
induced by either single agent or the combination of
both agents. And the level of p21 protein was also
down-regulated during this process (Figure 4F). As
shown in Figure 4D and E, HCCLM3 cells were treated
with rapamycin and/or bortezomib together with PFT-α for
48 h, the number of apoptotic cells was markedly decreased
in the presence of PFT-α from 23.8±3.7% to 15.1±2.5% in
bortezomib treatment group (P< 0.05) and 47.0±6.4% to
25.5±2.6% in the combined treatment group (P< 0.01).
The number of apoptotic cells did not obviously change in
rapamycin group during PFT-α treatment. Similar results
were also observed from Hoechst 33342 staining.
In vivo effects of rapamycin, bortezomib, or the
combination on tumor growth and lung metastasis
In order to determine whether the synergistic effect of
rapamycin and bortezomib in HCCLM3 cell line hasrelevant clinical implications, we used an orthotopic tumor
model to test the in vivo effect of rapamycin and/or borte-
zomib on the tumor growth and lung metastasis of HCC
xenograft tumors. Rapamycin significantly inhibited tumor
growth with average tumor volume of 0.77± 0.18 cm3, in
comparison with 1.70± 0.57 cm3 of the control mice
(P <0.01). Bortezomib decreased the tumor volume to
1.32± 0.54 cm3, but did not significantly differ with the
control (Figure 5C and D). The combination of rapamycin
and bortezomib significantly improved the tumor inhibi-
tory effect of rapamycin, with average tumor volume of
0.47± 0.07 cm3 (P< 0.05, Figure 5C and D). The rate of
tumor growth inhibition index by the combination treat-
ment was 72.4%, significantly higher than the rate in the
single agent group.
Toxicity observed with the combination treatment of
rapamycin and bortezomib was evidenced by 20% weight
loss at day 5 after initiation of treatment, which was
reversed after completion of treatment (Figure 5B). And
no significant abnormalities were found in these mice as
Figure 3 Rapamycin induced p-Akt in HCCLM3 cells, whereas
bortezomib inhibited p-Akt. (A) HCCLM3 cells were incubated
with culture media or rapamycin (1–100 ng/ml) for 24 h or
rapamycin (10 ng/ml) for the indicated periods. (B) HCCLM3 cells
were incubated for 24 h with culture media, bortezomib
(10–1000 nM), or bortezomib (100 nM) for the indicated time. (C)
Rapamycin is added to HCC cells for 3–6 h prior to the addition of
bortezomib, and then the cells were cultured for 24 h in the
presence of bortezomib at the concentration of 100 nM. (D, E)
HCCLM3 cells were cultured in control media, rapamycin (10 ng/ml),
bortezomib (100 nmol/L), or the combination of rapamycin and
bortezomib for 24 h. * P< 0.05, versus control group; ** P< 0.01,
versus control group; # P< 0.001, versus rapamycin treatment group.
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kidney tissues.
The presence of lung metastasis was determined by
both fluorescent imaging and HE staining. While 100%
of mice in the control group developed pulmonary me-
tastasis, rapamycin or bortezomib treatment caused a
reduction of the pulmonary metastasis of 50% and
33.4%, respectively (Figure 5E and F). However, the dif-
ference of pulmonary metastasis percentage between the
control group and either single agent group did not
reach statistical significance (P> 0.05). The combination
treatment of rapamycin and bortezomib significantly sup-
pressed pulmonary metastasis, with only one out of six
mice (16.6%) developed pulmonary metastasis (P< 0.05,
Fisher’s Exact test versus control group). Then we counted
the lung metastasis nodules of each mouse. We found thatthe median number of pulmonary nodules in rapamycin
and combined treatment group is 17.5 and 0, respectively,
which is obvious suppressed compared with control group
(Additional file 5: Table S2).
Effects of rapamycin and bortezomib alone or in
combination on proliferation, angiogenesis, and apoptosis
in HCC
To confirm the mechanism identified in vitro, the effect
of rapamycin and bortezomib on Akt phosphorylation
in vivo was assayed by immunohistochemistry and west-
ern blotting. Similar to the in vitro experiments, rapamy-
cin increased the level of p-Akt in HCC tumors after
30 days of treatment, which was abrogated by bortezo-
mib in the combination therapy (Figure 6A). Three
HCCLM3-R tumors from each treatment group were
further examined for Akt phosphorylation by western
blotting. As shown in Figure 6B, p-Akt was increased in
the HCCLM3-R tumors treated with rapamycin, but
decreased with bortezomib treatment. The combination of
rapamycin and bortezomib inhibited p-Akt in HCCLM3-R
tumors (Figure 6B).
To investigate whether rapamycin alone or in combin-
ation with bortezomib decrease HCC tumor growth by
inhibiting cell proliferation, we examined the number of
PCNA-positive cells in HCCLM3-R tumors from mice
with different treatments. The proliferation index in the
control group was 81.2 ± 5.8%. Rapamycin or bortezomib
significantly decreased tumor cell proliferation index to
62.8 ± 12.7% and 57.8 ± 10.6%, respectively (P< 0.05, ver-
sus the control group). The combination treatment of
rapamycin and bortezomib was significantly more effect-
ive in reducing PCNA expression (29.8 ± 6.5%) than ei-
ther agent alone (P< 0.01, versus monotherapy group,
Figure 6A and C).
The expression of the microvessel density marker
CD31 in orthotopic tumors from nude mice in different
treatment groups was also examined. The average num-
ber of CD31-positive vessels in the control group was
74.5 ± 18.5. Rapamycin reduced HCC vascularization with
49.5 ± 16.9 of CD31-positive vessel in tumors (Figure 6A
and D). Although bortezomib alone did not affect tumor
vascularization, the combination of bortezomib with
rapamycin significantly decreased the number of CD31-
positive vessels to 35 ± 7.0 (P< 0.01, versus the control;
P< 0.05, versus rapamycin alone) (Figure 6A and D).
Furthermore, the effect of rapamycin and/or bortezo-
mib on tumor cell apoptosis was examined by TUNEL.
The average number of apoptosis index was 0.56 ± 0.37%
in the control tumors. Bortezomib significantly increased
the number of apoptosis index to 2.52 ± 1.10%, compared
with the control mice (P< 0.01, Figure 6A and E). The
apoptosis index was not significant different between the
rapamycin-treated group (0.88 ± 0.38%) and the control
Figure 4 The pro-apoptotic effect of rapamycin plus bortezomib is dependent on p53 activity. (A, B) The mRNA expression levels of p53, p27,
p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR. Bcl-2 mRNA was significantly suppressed by the combined treatment of
rapamycin and bortezomib. The expression of p53, p27 p21and Bax mRNA was significantly up-regulated by monotherapy or the combination
therapy. (C) HCCLM3 cells were treated with rapamycin (10 ng/ml), bortezomib (100 nM) or the combination with or without PFT-α for 48 h and
stained with Hoechst 33342, the apoptotic nuclear changes were examined by fluorescence microscopy (magnification, ×400). (D, E) The
quantification of apoptotic cells was further confirmed by flow cytometry analysis. The sub-G1 contents were designed as apoptotic cells. (F) The
rapamycin plus bortezomib mediated up-regulation of p53 protein could be significantly suppressed by p53 inhibitor PFT-α. And the level of p21
protein was also down-regulated during this process. * P< 0.05, versus bortezomib group without PFT-α treatment; ** P< 0.01, versus combined
treatment group without PFT-α.
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Figure 5 The synergistic antitumor effects of rapamycin with bortezomib on orthotopic tumor model. (A) Schematic representation of the
experimental protocol as described in materials and methods. (B) Body weight was recorded to assess toxicity of treatment. (C) Tumors of mice
from each group on 5 wk after tumor implantation. (D) Average tumor volume of each group on 5 wk after tumor implantation. * P< 0.01, versus
control group; ** P< 0.001, versus control group; # P< 0.05, versus rapamycin treatment group. (E) The representative fluorescence images of
pulmonary metastasis (arrows) from each group on 5 wk in HCCLM3-R xenograft model (magnification, ×10). (F) The representative HE staining of
pulmonary metastasis (arrows) on 5 wk in HCCLM3-R xenograft model (magnification, ×200).
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zomib increased apoptosis index to 2.97 ± 1.24%, higher
than that in bortezomib alone, but without statistical sig-
nificance (Figure 6A and E).
Discussion
Due to unsatisfactory outcomes of available chemothera-
pies, new therapeutic strategies for HCC are urgently
needed. More effective treatments may involve combinationof agents with synergistic activity against HCC. Rapamycin,
a mTOR inhibitor, has been used in treating various solid
tumors. Despite its outstanding preclinical antitumor activ-
ity, rapamycin has been shown to increase Akt phosphoryl-
ation, which may counteract its anticancer efficacy [14,15]
And could be a reason why mTOR inhibitors only exhibit
modest antitumor activity in patients. In this study, we
hypothesized that the combined use of an agent which
down-regulates Akt survival pathway would potentiate the
Figure 6 In vivo mechanism of antitumor activity of rapamycin and bortezomib in xenograft model. (A) Ex vivo immunohistochemistry
staining of Akt, p-Akt, PCNA, CD31 or TUNEL in HCCLM3-R xenografts (magnification, ×200). The staining of p-Akt was increased in
rapamycin-treated tumors, but inhibited in bortezomib- or the combination-treated tumors. (B) The increase of p-Akt in rapamycin-treated tumors
and the decrease in bortezomib-treated tumors were also observed by Western blot analysis. Rapamycin-induced Akt phosphorylation was
abrogated by bortezomib in the combination-treated tumors. (A, C) Quantitation of PCNA positive cells demonstrated that rapamycin or
bortezomib significantly inhibited tumor growth, as compared with control (* P< 0.05), which was markedly enhanced by the combination of
both agents (** P< 0.01, versus control group and † P< 0.01 versus monotherapy). (A, D) The average number of CD31-positive vessels was
significantly reduced in tumors from the rapamycin monotherapy group (* P< 0.05, versus control group), which was further enhanced by the
combined therapy of rapamycin and bortezomib (** P< 0.01, versus control group; and # P< 0.05, versus rapamycin group). (A, E) The number of
TUNEL-positive cells in tumors was significantly elevated in bortezomib treatment group (** P< 0.01, versus control group) and the combined
treatment group (** P< 0.01, versus control group or rapamycin group).
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activation of Akt caused by mTOR inhibition, there are
some novel therapeutic approaches [32-34]. In our study,
we chose the combination of rapamycin with bortezomib
for a couple of reasons. Firstly, rapamycin and bortezomib
have shown single-agent activity in preclinical studies in
HCC. Secondly, PI3K/Akt/mTOR pathway is critical for cell
survival and resistance to apoptosis and both agents interact
at the PI3K/Akt/mTOR pathway [10,19], which is known to
be activated in HCC. Our results in this study have demon-
strated that suppression of mTOR signaling by rapamycin
in HCCLM3 cells was associated with up-regulation of Akt
phosphorylation, which was abrogated by bortezomib in a
dose-dependent manner. These in vitro results were also
confirmed in vivo, as bortezomib significantly suppressed
rapamycin-induced activation of Akt, which in turn
enhanced the rapamycin-induced inhibition of tumor
growth and pulmonary pulmonary metastasis in orthotopic
HCC mice. These data suggested that it is rational to com-
bine rapamycin with bortezomib for targeted HCC therapy.
Although rapamycin has been previously reported to in-
duce cell apoptosis [35], rapamycin treatment alone did not
induce apoptosis of HCCLM3 and SMMC7721 cells in this
study. However, we demonstrated that the combination of
rapamycin and bortezomib produced greater apoptotic ac-
tivity in HCCLM3 and SMMC7721 cells than either agent
alone. This synergistic apoptotic effect was at least partially
due to the suppression of rapamycin-induced Akt activation
by bortezomib, which may overcome rapamycin resistance.
In addition, our data demonstrated that the combination of
rapamycin and bortezomib significantly enhanced the ex-
pression of p53 mRNA, which may lead to an irreversible
apoptotic commitment. The activation of p53 may also con-
tribute to apoptosis by inhibiting Akt phosphorylation
[36,37]. Once activated, p53 induces up-regulation of p21
and Bax, which mediate different aspects of p53 function
on proliferation arrest and apoptosis [38,39]. Our data sug-
gested that the pro-apoptotic effect of rapamycin plus bor-
tezomib involves elevated transcriptional activity of p53.
P53 inhibitor PFT-α can attenuate the pro-apoptotic effect
of the combined treatment. Based on our results, we
propose that the combined treatment induced apoptosis in
HCCLM3 cells is mainly, if not completely, dependent on
p53 activity.
The expression of p27 mRNA in HCCLM3 cells was
also significantly up-regulated by rapamycin or the com-
bination of rapamycin and bortezomib. Moss et al.
reported that rapamycin increased p27 levels, which
inhibited migration of human umbilical vein endothelial
cells (HUVECs) and human coronary artery endothelial
cells (HCAEC). Silencing of p27 with small interfering
RNA blocked the effects of rapamycin on migration and
tube formation [40]. Although the link between mTOR
inhibition and cell migration need further investigation,the increased level of p27 induced by rapamycin or the
combination treatment may be a potential molecular
mechanism involved in the regulation of HCCLM3 cell
migration.
Furthermore, we examined the effects of rapamycin
and/or bortezomib in orthotopic tumor model of HCC.
Rapamycin alone significantly inhibited HCCLM3-R
tumor growth. Bortezomib produced less growth inhib-
ition in HCCLM3-R tumors as compared to rapamycin,
even though bortezomib induced higher level of apop-
tosis in HCCLM3 cells in vitro. The combination of
rapamycin and bortezomib generated greater tumor
growth inhibition than either agent alone, with the rate
of tumor growth inhibition index as high as 72.4%.
Moreover, only 16.6% of mice (1/6) developed pulmon-
ary metastasis in the combination treatment group. Our
data demonstrated that bortezomib down-regulated the
rapamycin-induced activation of Akt in tumor tissues,
which may be one of mechanisms of the novel synergis-
tic antitumor effects. The average proliferation index was
dramatically decreased from 62.8 ± 12.7% in rapamycin
treatment group to 29.8 ± 6.5% in the group that received
both rapamycin and bortezomib. Rapamycin has showed
antiangiogenic activities in vivo not only by decreasing
the production of VEGF but also by inhibiting the re-
sponse of vascular endothelial cells on stimulation by
VEGF via inhibiting of mTOR [41]. One mechanism of
bortezomib-induced tumor growth inhibition identified
in previous studies is also angiogenesis inhibition [42]. In
our study, rapamycin, but not bortezomib, significantly
reduced microvessel density in orthotopic HCC tumors.
The combination of rapamycin and bortezomib amplified
the rapamycin-induced inhibition of tumor angiogenesis
from 33.6% to 53.0%.The mechanism of synergistic in-
hibition of angiogenesis by these agents is still unclear
and needs further investigation.
In this study, we demonstrated the synergistic effects
of rapamycin and bortezomib in inhibiting cell growth,
inducing cell apoptosis, and suppressing cell migration
and invasion in vitro. Rapamycin alone or in combin-
ation with bortezomib, strongly inhibited HCC growth
and pulmonary metastasis in vivo. Bortezomib overcame
rapamycin resistance in HCC cells partly through inhib-
ition of the PI3K/Akt pathway activated by rapamycin. In
summary, this study provides preclinical evidence that
the combination of rapamycin and bortezomib could be
a novel and promising therapeutic approach to the treat-
ment of HCC, which warrants further investigation in a
clinical setting.
Conclusions
Rapamycin combined with bortezomib exhibited syner-
gistic antitumor effects on experimental HCC growth
and metastasis. It should be a novel and promising
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worth further studies in patients with HCC, especially
disease at advanced stages.
Additional Files
Additional file 1: Table S1. RT-PCR primer sequences and reaction
conditions.
Additional file 2: Figure S1. Combined treatment with rapamycin and
bortezomib inhibits SMMC7721 proliferation. (A) Proliferation of
SMMC7721 cells was evaluated by using Cell Counting Kit-8 (CCK-8) at
indicated time points. (B) SMMC7721 cells were treated with rapamycin
(10 ng/ml), bortezomib (100 nM) or both agents. Cell cycle analysis was
carried out after 24 h. One representative experiment of three is shown.
Additional file 3: Figure S2. Rapamycin plus bortezomib causes
enhanced apoptosis. (A) SMMC7721 cells were treated with rapamycin
(10 ng/ml), bortezomib (100 nM) or the combination for 24 or 48 h and
stained with Hoechst 33342 (magnification, ×400). (B, C) The
quantification of apoptotic cells induced by rapamycin and bortezomib
was further confirmed by flow cytometry analysis. * P < 0.01, versus
control group; ** P < 0.001, versus control group; # P < 0.05, versus
bortezomib treatment group at 48 h.
Additional file 4: Figure S3. Bortezomib significantly suppressed
rapamycin mediated Akt phosphorylation in SMMC7721 cells. (A, B)
SMMC7721 cells were cultured in control media, rapamycin (10 ng/ml),
bortezomib (100 nmol/L), or rapamycin and bortezomib for 24 h. * P <
0.05, versus control group; ** P < 0.01, versus control group; # P < 0.01,
versus rapamycin treatment group.
Additional file 5: Table S2. Lung metastasis in HCCLM3-R xenograft
model.
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